Clinical Trials Logo

Filter by:
NCT ID: NCT03183921 Recruiting - Pneumonia Clinical Trials

Study on ICU Patients With Nosocomial Lower Respiratory Tract Infections

ENIRRIs
Start date: September 1, 2016
Phase: N/A
Study type: Observational [Patient Registry]

This is a multicentre, multinational, prospective observational investigation on ICU critically ill patients affected by nosocomial pneumonia, defined as: Out of ICU Hospital-acquired Pneumonia (HAP), Non-ventilator ICU-acquired Pneumonia (NV ICUAP), Ventilator associated pneumonia (VAP) Ventilator associated tracheobronchitis (VAT).

NCT ID: NCT03171311 Active, not recruiting - Clinical trials for Ischemic Heart Disease

The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)

OCTOBER
Start date: July 5, 2017
Phase: N/A
Study type: Interventional

The purpose is to compare median two-year clinical outcome after OCT guided vs. standard guided revascularization of patients requiring complex bifurcation stent implantation

NCT ID: NCT03167320 Recruiting - Clinical trials for Von Willebrand Factor, Deficiency

Low Von Willebrand in Ireland Cohort Study

LOVIC
Start date: October 2014
Phase:
Study type: Observational

The Low Von Willebrand in Ireland Cohort (LoVIC) study focuses on the bleeding phenotype and biological mechanisms underlying low Von Willebrand Factor (VWF) levels.

NCT ID: NCT03166735 Completed - Clinical trials for Non-alcoholic Fatty Liver Disease

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

Start date: June 6, 2017
Phase: Phase 2
Study type: Interventional

The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH. To gain further insight into clinical effects of AOC3 inhibition on NASH further exploratory analyses of biomarkers related to NASH and liver fibrosis will be performed. This will include the effect of BI 1467335 on reduction of secondary biomarker endpoints (ALT, AST, AP, γ-GT and CK18 fragments). Safety will be assessed throughout the study to provide key information regarding the use of BI 1467335 in patients with NASH.

NCT ID: NCT03166722 Completed - Brain Injuries Clinical Trials

Cerebral Regional Tissue Oxygen Saturation to Guide Oxygen Delivery in Preterm Neonates During Immediate Transition

COSGOD
Start date: September 20, 2017
Phase: N/A
Study type: Interventional

The aim of the COSGOD Phase III trial is to examine, if it is possible to increase survival without cerebral injury in preterm neonates <32 weeks of gestation by monitoring the cerebral tissue oxygen saturation in addition to routine monitoring of arterial oxygen saturation and heart rate and specified clinical treatment guidelines during immediate transition period after birth (the first 15 minutes).

NCT ID: NCT03162003 Completed - Prostate Cancer Clinical Trials

Irish Programme for Stratified Prostate Cancer Therapy

iPROSPECT
Start date: February 2015
Phase:
Study type: Observational

The purpose of the trial is to investigate new clinical tests that could predict what treatments work best for certain patients with advanced prostate cancer by identifying markers and indicators present in blood and tissue which correlate with treatment response.

NCT ID: NCT03160898 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)

FORTITUDE-ALS
Start date: July 24, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the effect of CK-2127107 (hereafter referred to as reldesemtiv) versus placebo on respiratory function and other measures of skeletal muscle function in patients with ALS.

NCT ID: NCT03160066 Completed - Healthy Clinical Trials

The Effects of Lactobacillus Rhamnosus (JB-1) on Stress and Cognition

Start date: July 2015
Phase: N/A
Study type: Interventional

Emerging evidence suggests that microorganisms acting via the Brain-Gut axis may have potential benefits for the management of stress-related conditions. The majority of studies have focused on animal models. Preclinical studies have identified the Lactobacillus Rhamnosus JB-1 strain as a putative psychobiotic with an impact on stress-related behaviours, physiology and cognitive performance. Whether such preclinical effects could be translated to healthy human volunteers remains unknown.

NCT ID: NCT03155243 Completed - Uveitis Clinical Trials

Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice

HOPE
Start date: June 20, 2017
Phase:
Study type: Observational

This study aims at evaluating real life effectiveness of originator adalimumab (Humira®) participants with active non-infectious intermediate, posterior and panuveitis (NIIPPU) despite high-dose corticosteroid therapy; including effect on ocular inflammation, health-related quality of life, health resource utilization, work ability and medication burden, as well as describe the characteristics of NIIPPU participants treated with Humira® in the real-life setting.

NCT ID: NCT03153475 Active, not recruiting - Clinical trials for Revision Total Knee Arthroplasty

ATTUNE Revision System in the Revision Total Knee Arthroplasty Population

Start date: May 30, 2017
Phase: N/A
Study type: Interventional

Five-year, Prospective, multi-center, non-randomized, non-controlled study of the ATTUNE® Revision total knee prostheses, utilizing the fixed bearing (FB) and rotating platform (RP) tibial component with the posterior stabilizing (PS) femoral component in revision total knee arthroplasty.